title: Norsalsolinol uptake into secretory vesicles via vesicular monoamine transporter and its secretion by membrane depolarization or purinoceptor stimulation in PC12 cells.
abstract: The intracellular dynamics of norsalsolinol, a neurotoxin candidate causing parkinsonism-like symptoms, in PC12 cells was studied. We found that dopamine and norsalsolinol are co-localized to secretory granule layer by sucrose density gradient in norsalsolinol-treated PC12 cells. The norsalsolinol was actively taken up into isolated secretory vesicle fraction from PC12 cells with a Km value of 41.5+/-6.8 microM. The uptake of 10 microM of norsalsolinol was sensitive to reserpine (1 microM), an inhibitor of vesicular dopamine transporter, and dopamine, an endogenous substrate, but insensitive to GBR-12909, an inhibitor of dopamine transporter on plasma membrane. In norsalsolinol-treated PC12 cells, exposure to high K+ or ATP resulted in simultaneous release of norsalsolinol and dopamine. Time course of a release of dopamine and that of norsalsolinol evoked by 50 mM KCl or 100 microM ATP corresponded to each other. These releases were dependent on the concentrations of secretagogues. These data suggest that norsalsolinol is taken up with dopamine into secretory vesicle via vesicular catecholamine transporter.
authors: Department of Environmental Veterinary Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, Japan.
authors: Y
authors: Y
authors: Maruyama
authors: Y
authors: Y
authors: Suzuki
authors: A
authors: A
authors: Kazusaka
authors: S
authors: S
authors: Fujita
mesh_terms: D000255:Adenosine Triphosphate / Q000502:physiology; D018759:Adrenergic Uptake Inhibitors / Q000494:pharmacology; D000818:Animals; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D050482:Catecholamine Plasma Membrane Transport Proteins; D002478:Cells, Cultured; D002499:Centrifugation, Density Gradient; D004298:Dopamine / Q000378:metabolism; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology; D026901:Membrane Transport Proteins; D016716:PC12 Cells; D010879:Piperazines / Q000494:pharmacology; D011188:Potassium / Q000502:physiology; D051381:Rats; D011983:Receptors, Purinergic / Q000502:physiology*; D012110:Reserpine / Q000494:pharmacology; D012490:Salsoline Alkaloids / Q000493:pharmacokinetics* / Q000494:pharmacology; D022142:Secretory Vesicles / Q000187:drug effects / Q000378:metabolism*; D013347:Subcellular Fractions / Q000378:metabolism
chemical_list: D018759:Adrenergic Uptake Inhibitors; D002352:Carrier Proteins; D050482:Catecholamine Plasma Membrane Transport Proteins; D018765:Dopamine Uptake Inhibitors; D026901:Membrane Transport Proteins; D010879:Piperazines; D011983:Receptors, Purinergic; D012490:Salsoline Alkaloids; C493212:Slc22a1 protein, rat; D012110:Reserpine; D000255:Adenosine Triphosphate; C043425:vanoxerine; C020784:norsalsolinol; D011188:Potassium; D004298:Dopamine